Tennessee Code Title 33. Mental Health and Substance Abuse and Intellectual and Developmental Disabilities § 33-2-1401

(1) “Alcohol and drug prevention or treatment facility” or “ADTF”:

(2) ”Alcohol and drug services” includes evaluation, treatment, residential personal care, habilitation, rehabilitation, counseling, or supervision of persons with substance use disorder, or services to persons designed to prevent substance use disorder that either receive funds from the department of health or assess fees for services provided;  however, a DUI school operated by a state institution of higher education is not considered alcohol and drug services for purposes of this part;

(3) “Levels of care” means the continuum of support ranging from nonclinical recovery housing to clinical and licensed treatment;

(4) “Municipality” means an incorporated city or town, or a county with a metropolitan form of government;

(5) “Organization” means any nationally recognized recovery residence standards organization, any affiliate of any nationally recognized recovery residence standards organization, or grantees of any state or federal department or agency;

(6) “Peer” means an individual with lived experience in recovery and the appropriate skills to support a recovery community;

(7) “Recovery residence” means a residence classified as a single family residence, as defined in § 13-24-102, or any other premise, place, or building that provides a substance-free living environment centered on supervised, monitored, or peer-led support that assists individuals in recovery from substance use disorder with services that promote long-term recovery, including direct connection to other peers in recovery, mutual support groups, and recovery support services but does not provide any medical or clinical services, treatment, or medication administration on-site except for verification of abstinence;  and

(8) “Substance-free” does not mean free of substances that are prescription medications taken as directed by a licensed prescriber, such as pharmacotherapies specifically approved by the federal food and drug administration (FDA) for the treatment of opioid use disorder, as well as other medications with FDA-approved indications for the treatment of co-occurring disorders.